1. South Korea Stocks

  2. •

    Transportation

  3. •

    Other transportation
MEDIPOST Co., Ltd.

MEDIPOST Co., Ltd.

KKRX:078160
8,470.00
KRW
-110.00
(-1.28%)
-2,226.77EPS
828.61BMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,531.01
2,474.96
2,189.2
1,600.14
2,355.89
1,238.12
2,545.52
2,695.04
2,973.2
3,423.49
3,373.38
2,072.53
2,076.93
2,052.09
Basic EPS, GAAP
60.72
-110.67
161.91
-625.25
-52.97
-55.98
-784.58
-105.07
-37.03
163.63
287
-1,834
-2,408
-2,209.6
Free Cash Flow per Basic Share
-2,136.06
-1,964.36
-900.92
-801.92
-454.01
138.95
120.29
-348.07
-360.32
-474.89
-1,066.01
-1,188.72
-1,703.76
-1,638.31
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7,114.11
7,083.29
8,226.36
5,603.95
5,811.36
7,046.67
6,200.66
6,476.01
8,507.01
9,600.07
9,136.82
7,370.07
6,371.12
6,153.07
Tangible Book Value per Share
4,612.05
4,299.47
5,667.18
5,076.84
5,356.66
6,672.66
5,862.83
6,233.5
8,150.15
9,372.75
9,009.47
7,248.05
6,278.87
6,060.26
Basic Weighted Avg Shares
16
17
17
18
18
36
18
18
18
19
20
34
35
36
Sales/Revenue/Turnover
41,504
41,403
37,570
28,654
42,250
44,384
45,811
48,625
54,856
64,201
68,643
70,657
73,657
73,896
Operating Margin (%)
-0.48
-4.29
-0.56
-53.78
-8.05
-14.85
-17.6
-4.96
-9.5
-27.13
-36.65
-68.7
-92.3
-96.31
Depreciation Expense
2,797
3,153
4,753
4,382
5,136
4,655
4,863
5,103
4,898
5,382
5,872
6,022
5,986
5,583
Net Income, GAAP
996
-1,851
2,779
-11,196
-950
-2,007
-14,120
-1,896
-683
3,069
5,840
-62,525
-85,398
-79,568
Effective Tax Rate (%)
14.42
- -
- -
- -
- -
- -
- -
717.08
260.42
67.65
- -
- -
- -
- -
Profit Margin (%)
2.4
-4.47
7.4
-39.07
-2.25
-4.52
-30.82
-3.9
-1.25
4.78
8.51
-88.49
-115.94
-107.68
Working Capital
34,367
45,040
24,649
35,123
36,767
35,734
22,703
17,603
39,684
-2,777
130,190
53,795
31,477
20,038
LT Debt
7,745
44,690
2,342
15,595
15,595
- -
354
271
1,229
1,240
7,985
7,618
966
935
Total Equity
117,423
117,338
146,482
100,712
104,439
126,804
111,959
116,915
162,193
182,578
313,657
252,601
249,907
241,254
Return on Invested Capital (%)
-0.14
- -
- -
- -
- -
- -
- -
9.9
4.87
-2.7
- -
- -
- -
- -
Return on Capital (%)
0.73
- -
- -
- -
- -
- -
- -
-26
-3.48
3.16
- -
- -
- -
- -
Return on Common Equity (%)
0.86
-1.59
2.11
-9.06
-0.93
-1.74
-11.85
-1.66
-0.5
1.81
2.38
-22.22
-34.14
-33.44

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10,652
39,434
153,643
LT Borrowings
- -
- -
- -
LT Finance Leases
1,080
966
935
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
531,955
710,967
828,615

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
88,545
128,285
269,522
Cash, Cash Equivalents & STI
37,679
78,034
217,655
Accounts Receivable, Net
12,848
11,846
11,843
Inventories
16,691
20,775
22,540
Total Current Liabilities
29,911
96,808
249,483
Payables & Accruals
- -
- -
- -
ST Debt
10,652
39,434
153,643
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.91%
20.51%
-1.07%
Free Cash Flow
-33.89%
63.86%
49.1%
Net Income, GAAP
-162.3%
-331.36%
36.58%
Sales/Revenue/Turnover
8.21%
8.79%
4.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,031
17,516
17,275
17,836
70,657
2025
19,225
17,836
18,689
17,908
73,657
2026
19,464
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-200.62
84
-534
-1,182.54
-1,834
2025
-480
-708.92
-535.81
-711.82
-2,408
2026
-269.92
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Won-Il Oh
Full Time Employees
342
Sector
Transportation
Industry
Other transportation
Address
Seongnam-si GY South Korea
IPO Date
Jul 29, 2005
Website
medi-post.co.kr
Similar Companies
Uber Technologies, Inc. (NYSE:UBER)
Adani Ports & Special Economic Zone Ltd (NSE:ADANIPORTS)
TAV Havalimanlari Holding A.S. (BIST:TAVHL)
Lyft, Inc. (NASDAQ:LYFT)
Wetour Robotics Limited (NASDAQ:WETO)
GMR Airports Ltd (NSE:GMRAIRPORT)
Business
MEDIPOST Co., Ltd. engages in biotechnology, primarily developing and commercializing umbilical cord blood-derived mesenchymal stem cell therapies; operating cord blood banking services; producing health functional foods and nutritional supplements; and providing contract development and manufacturing organization (CDMO) services for cell and gene therapies. The company offers CARTISTEM, a regulatory-approved product for treating knee cartilage defects and osteoarthritis; PNEUMOSTEM, in development for preventing bronchopulmonary dysplasia; next-generation SMUP-platform products including SMUP-IA-01 for knee osteoarthritis (Phase 2 trials completed in 2024) and SMUP-IV-01 for diabetic nephropathy; cord blood banking under the CELLTREE brand, encompassing public and family storage with transplant services; nutritional supplements under the MOVITA brand tailored by age, gender, and lifestyle; and CDMO capabilities through its subsidiary OmniaBio. Founded in 2000 and headquartered in Seongnam-si, South Korea, MEDIPOST operates internationally with subsidiaries in the United States (MEDIPOST Inc., Cambridge, MA), Canada (OmniaBio Inc., Hamilton, ON), and Japan (MEDIPOST K.K., Tokyo); it targets patients with unmet needs in regenerative medicine, blood-related diseases, and chronic conditions across Korea, North America, Asia, and select global markets including clinical trials and transplants in the US, Canada, Sweden, and Australia. Recent developments include completion of Phase 3 clinical trial administration for CARTISTEM in knee osteoarthritis (November 2024); OmniaBio's opening of a new CGT CDMO facility in Canada (October 2024); recruitment of local experts for its US subsidiary to accelerate North American expansion (December 2024); CARTISTEM reaching a milestone of treating 30,000 patients (June 2024); and a product authorization amendment application to add ankle indications (December 2023).